Fulminant Myocarditis with Combination Immune Checkpoint Blockade
2016 · New England Journal of Medicine · 2,189 citations
https://doi.org/10.1056/nejmoa1609214
I
Igor Puzanov
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
669
Papers
55.5K
Citations
91
h-index
260
i10-index
Igor Puzanov is an academic researcher from Roswell Park Comprehensive Cancer Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 91, co-authored 569 publications.
ORCID: 0000-0002-9803-3497Papers by this author
worksManaging toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
2017 · Journal for ImmunoTherapy of Cancer · 1,913 citations
https://doi.org/10.1186/s40425-017-0300-z
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
2017 · Cell · 1,437 citations
https://doi.org/10.1016/j.cell.2017.08.027
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
2021 · Journal for ImmunoTherapy of Cancer · 772 citations
https://doi.org/10.1136/jitc-2021-002435
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
2016 · Nature Communications · 558 citations
https://doi.org/10.1038/ncomms10582
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
2016 · Journal of Clinical Oncology · 545 citations
https://doi.org/10.1200/jco.2016.67.1529
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat